|
1
|
Bubendorf L, Schöpfer A, Wagner U, et al:
Metastatic patterns of prostate cancer: an autopsy study of 1,589
patients. Hum Pathol. 31:578–583. 2000.
|
|
2
|
Roehl KA, Han M, Ramos CG, Antenor JA and
Catalona WJ: Cancer progression and survival rates following
anatomical radical retropubic prostatectomy in 3,478 consecutive
patients: long-term results. J Urol. 172:910–914. 2004.
|
|
3
|
Hull GW, Rabbani F, Abbas F, Wheeler TM,
Kattan MW and Scardino PT: Cancer control with radical
prostatectomy alone in 1,000 consecutive patients. J Urol.
167:528–534. 2002.
|
|
4
|
Daneshgari F and Crawford ED: Endocrine
therapy of advanced carcinoma of the prostate. Cancer.
71:1089–1097. 1993.
|
|
5
|
Eymard JC, Oudard S, Gravis G, et al:
Docetaxel reintroduction in patients with metastatic
castration-resistant docetaxel-sensitive prostate cancer: a
retrospective multicentre study. BJU Int. 106:974–978. 2010.
|
|
6
|
Folkman J, Cole P and Zimmerman S: Tumor
behavior in isolated perfused organs: in vitro growth and
metastases of biopsy material in rabbit thyroid and canine
intestinal segment. Ann Surg. 164:491–502. 1966.
|
|
7
|
Banerjee S, Dowsett M, Ashworth A and
Martin LA: Mechanisms of disease: angiogenesis and the management
of breast cancer. Nat Clin Pract Oncol. 4:536–550. 2007.
|
|
8
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
|
|
9
|
Bigler SA, Deering RE and Brawer MK:
Comparison of microscopic vascularity in benign and malignant
prostate tissue. Hum Pathol. 24:220–226. 1993.
|
|
10
|
Stefanou D, Batistatou A, Kamina S,
Arkoumani E, Papachristou DJ and Agnantis NJ: Expression of
vascular endothelial growth factor (VEGF) and association with
microvessel density in benign prostatic hyperplasia and prostate
cancer. In Vivo. 18:155–160. 2004.
|
|
11
|
Weidner N, Carroll PR, Flax J, Blumenfeld
W and Folkman J: Tumor angiogenesis correlates with metastasis in
invasive prostate carcinoma. Am J Pathol. 143:401–409. 1993.
|
|
12
|
Borre M, Offersen BV, Nerstrom B and
Overgaard J: Microvessel density predicts survival in prostate
cancer patients subjected to watchful waiting. Br J Cancer.
78:940–944. 1998.
|
|
13
|
Brawer MK, Deering RE, Brown M, Preston SD
and Bigler SA: Predictors of pathologic stage in prostatic
carcinoma. The role of neovascularity. Cancer. 73:678–687.
1994.
|
|
14
|
Bostwick DG, Wheeler TM, Blute M, et al:
Optimized microvessel density analysis improves prediction of
cancer stage from prostate needle biopsies. Urology. 48:47–57.
1996.
|
|
15
|
Silberman MA, Partin AW, Veltri RW and
Epstein JI: Tumor angiogenesis correlates with progression after
radical prostatectomy but not with pathologic stage in Gleason sum
5 to 7 adenocarcinoma of the prostate. Cancer. 79:772–779.
1997.
|
|
16
|
Bono AV, Celato N, Cova V, Salvadore M,
Chinetti S and Novario R: Microvessel density in prostate
carcinoma. Prostate Cancer Prostatic Dis. 5:123–127. 2002.
|
|
17
|
Byrne AM, Bouchier-Hayes DJ and Harmey JH:
Angiogenic and cell survival functions of vascular endothelial
growth factor (VEGF). J Cell Mol Med. 9:777–794. 2005.
|
|
18
|
Dvorak HF, Detmar M, Claffey KP, Nagy JA,
van de Water L and Senger DR: Vascular permeability factor/vascular
endothelial growth factor: an important mediator of angiogenesis in
malignancy and inflammation. Int Arch Allergy Immunol. 107:233–235.
1995.
|
|
19
|
Duque JL, Loughlin KR, Adam RM, Kantoff
PW, Zurakowski D and Freeman MR: Plasma levels of vascular
endothelial growth factor are increased in patients with metastatic
prostate cancer. Urology. 54:523–527. 1999.
|
|
20
|
George DJ, Halabi S, Shepard TF, et al:
Cancer and Leukemia Group B 9480: Prognostic significance of plasma
vascular endothelial growth factor levels in patients with
hormone-refractory prostate cancer treated on Cancer and Leukemia
Group B 9480. Clin Cancer Res. 7:1932–1936. 2001.
|
|
21
|
Peyromaure M, Camparo P, Badoual C,
Descazeaud A and Dinh-Xuan AT: The expression of vascular
endothelial growth factor is associated with the risk of cancer
progression after radical prostatectomy. BJU Int. 99:1150–1153.
2007.
|
|
22
|
Bok RA, Halabi S, Fei DT, et al: Vascular
endothelial growth factor and basic fibroblast growth factor urine
levels as predictors of outcome in hormone-refractory prostate
cancer patients: a cancer and leukemia group B study. Cancer
research. 61:2533–2536. 2001.
|
|
23
|
Green MM, Hiley CT, Shanks JH, et al:
Expression of vascular endothelial growth factor (VEGF) in locally
invasive prostate cancer is prognostic for radiotherapy outcome.
Int J Radiat Oncol Biol Phys. 67:84–90. 2007.
|
|
24
|
Huss WJ, Hanrahan CF, Barrios RJ, Simons
JW and Greenberg NM: Angiogenesis and prostate cancer:
identification of a molecular progression switch. Cancer Res.
61:2736–2743. 2001.
|
|
25
|
Wennerberg K, Rossman KL and Der CJ: The
Ras superfamily at a glance. J Cell Sci. 118:843–846. 2005.
|
|
26
|
Bustelo XR, Sauzeau V and Berenjeno IM:
GTP-binding proteins of the Rho/Rac family: regulation, effectors
and functions in vivo. Bioessays. 29:356–370. 2007.
|
|
27
|
Etienne-Manneville S and Hall A: Rho
GTPases in cell biology. Nature. 420:629–635. 2002.
|
|
28
|
Bourne HR, Sanders DA and McCormick F: The
GTPase superfamily: conserved structure and molecular mechanism.
Nature. 349:117–127. 1991.
|
|
29
|
Bourne HR, Sanders DA and McCormick F: The
GTPase superfamily: a conserved switch for diverse cell functions.
Nature. 348:125–132. 1990.
|
|
30
|
Spiering D and Hodgson L: Dynamics of the
Rho-family small GTPases in actin regulation and motility. Cell Adh
Migr. 5:170–180. 2011.
|
|
31
|
Horowitz S, Binion DG, Nelson VM, et al:
Increased arginase activity and endothelial dysfunction in human
inflammatory bowel disease. Am J Physiol Gastrointest Liver
Physiol. 292:G1323–G1336. 2007.
|
|
32
|
Ming XF, Barandier C, Viswambharan H, et
al: Thrombin stimulates human endothelial arginase enzymatic
activity via RhoA/ROCK pathway: implications for atherosclerotic
endothelial dysfunction. Circulation. 110:3708–3714. 2004.
|
|
33
|
Somlyo AP and Somlyo AV: Ca2+
sensitivity of smooth muscle and nonmuscle myosin II: modulated by
G proteins, kinases and myosin phosphatase. Physiological reviews.
83:1325–1358. 2003.
|
|
34
|
Pertz O, Hodgson L, Klemke RL and Hahn KM:
Spatiotemporal dynamics of RhoA activity in migrating cells.
Nature. 440:1069–1072. 2006.
|
|
35
|
Kurokawa K and Matsuda M: Localized RhoA
activation as a requirement for the induction of membrane ruffling.
Mol Biol Cell. 16:4294–4303. 2005.
|
|
36
|
Machacek M, Hodgson L, Welch C, et al:
Coordination of Rho GTPase activities during cell protrusion.
Nature. 461:99–103. 2009.
|
|
37
|
Sakamoto S, Ryan AJ and Kyprianou N:
Targeting vasculature in urologic tumors: mechanistic and
therapeutic significance. J Cell Biochem. 103:691–708. 2008.
|
|
38
|
Mehta D and Malik AB: Signaling mechanisms
regulating endothelial permeability. Physiol Rev. 86:279–367.
2006.
|
|
39
|
Dudek SM and Garcia JG: Cytoskeletal
regulation of pulmonary vascular permeability. J Appl Physiol
(1985). 91:1487–1500. 2001.
|
|
40
|
Sun H, Breslin JW, Zhu J, Yuan SY and Wu
MH: Rho and ROCK signaling in VEGF-induced microvascular
endothelial hyperpermeability. Microcirculation. 13:237–247.
2006.
|
|
41
|
Kiosses WB, Daniels RH, Otey C, Bokoch GM
and Schwartz MA: A role for p21-activated kinase in endothelial
cell migration. J Cell Biol. 147:831–844. 1999.
|
|
42
|
van Nieuw Amerongen GP, Koolwijk P,
Versteilen A and van Hinsbergh VW: Involvement of RhoA/Rho kinase
signaling in VEGF-induced endothelial cell migration and
angiogenesis in vitro. Aterioscler Thromb Vasc Biol. 23:211–217.
2002.
|
|
43
|
Zhao L, Xu G, Zhou J, et al: The effect of
RhoA on human umbilical vein endothelial cell migration and
angiogenesis in vitro. Oncol Rep. 15:1147–1152. 2006.
|
|
44
|
Van Aelst L and D’Souza-Schorey C: Rho
GTPases and signaling networks. Genes Dev. 11:2295–2322. 1997.
|
|
45
|
Glotzer M: Animal cell cytokinesis. Annu
Rev Cell Dev Biol. 17:351–386. 2001.
|
|
46
|
Bobak D, Moorman J, Guanzon A, Gilmer L
and Hahn C: Inactivation of the small GTPase Rho disrupts cellular
attachment and induces adhesion-dependent and adhesion-independent
apoptosis. Oncogene. 15:2179–2189. 1997.
|
|
47
|
Petrache I, Crow MT, Neuss M and Garcia
JG: Central involvement of Rho family GTPases in TNF-alpha-mediated
bovine pulmonary endothelial cell apoptosis. Biochem Biophys Res
Commun. 306:244–249. 2003.
|
|
48
|
Yin L, Morishige K, Takahashi T, et al:
Fasudil inhibits vascular endothelial growth factor-induced
angiogenesis in vitro and in vivo. Mol Cancer Ther. 6:1517–1525.
2007.
|
|
49
|
Bryan BA, Dennstedt E, Mitchell DC, et al:
RhoA/ROCK signaling is essential for multiple aspects of
VEGF-mediated angiogenesis. FASEB J. 24:3186–3195. 2010.
|
|
50
|
Montesano R, Orci L and Vassalli P: In
vitro rapid organization of endothelial cells into capillary-like
networks is promoted by collagen matrices. J Cell Biol.
97:1648–1652. 1983.
|
|
51
|
Ghosh K, Thodeti CK, Dudley AC, Mammoto A,
Klagsbrun M and Ingber DE: Tumor-derived endothelial cells exhibit
aberrant Rho-mediated mechanosensing and abnormal angiogenesis in
vitro. Proc Natl Acad Sci USA. 105:11305–11310. 2008.
|
|
52
|
Somlyo AV, Bradshaw D, Ramos S, Murphy C,
Myers CE and Somlyo AP: Rho-kinase inhibitor retards migration and
in vivo dissemination of human prostate cancer cells. Biochem
Biophys Res Commun. 269:652–659. 2000.
|
|
53
|
Somlyo AV, Phelps C, Dipierro C, et al:
Rho kinase and matrix metalloproteinase inhibitors cooperate to
inhibit angiogenesis and growth of human prostate cancer
xenotransplants. FASEB J. 17:223–234. 2003.
|
|
54
|
Wu Y, He L, Zhang L, et al: Anacardic acid
(6-pentadecylsalicylic acid) inhibits tumor angiogenesis by
targeting Src/FAK/Rho GTPases signaling pathway. J Pharmacol Exp
Ther. 339:403–411. 2011.
|
|
55
|
Shimokawa H, Hiramori K, Iinuma H, et al:
Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients
with stable effort angina: a multicenter study. J Cardiovasc
Pharmacol. 40:751–761. 2002.
|
|
56
|
Fukumoto Y, Matoba T, Ito A, et al: Acute
vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients
with severe pulmonary hypertension. Heart. 91:391–392. 2005.
|
